@article{JTD22676,
author = {Kentaro Ito and Osamu Hataji},
title = {Osimertinib therapy as first-line treatment before acquiring T790M mutation: from AURA1 trial},
journal = {Journal of Thoracic Disease},
volume = {10},
number = {Suppl 26},
year = {2018},
keywords = {},
abstract = {First- or second-generation EGFR tyrosine kinase inhibitors (EGFR-TKI) have been the first-line treatment for NSCLC harboring EGFR mutation (1-6), however almost all patients inevitably acquire resistance during EGFR-TKI therapy.},
issn = {2077-6624}, url = {https://jtd.amegroups.org/article/view/22676}
}